JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr

JOHNSON & JOHNSON

2026-Q1 EPS reported $2.14 revenue$24,062,000,000

Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).
GAAP net earnings $5.24B ($2.14 diluted EPS) vs $11.0B ($4.54) in Q1 2025, down 52% due to prior-year other income.
Adjusted net earnings $6.61B ($2.70 diluted EPS) vs $6.71B ($2.77), down 1.4% YoY.
Dividend increased 3.1% to $1.34 per quarter ($5.36 annual), marking 64th consecutive annual increase; payable June 9, 2026 to record May 26.
Innovative Medicine segment sales $15.4B (+11.2%); MedTech $8.6B (+7.7%).

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

JOHNSON & JOHNSON reported first quarter ended March 29, 2026 results: revenue $24,062, net income $5,235, EPS $2.14.

Period: first quarter ended March 29, 2026
Revenue: $24,062
Net income: $5,235
EPS: $2.14
Result: reported results

Exact text from the filing

5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide $24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and subsidiaries

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0000200406-26-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.